Status:
COMPLETED
Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the effectiveness of biphasic insulin aspart 30 in type 2 diabetics not achieving blood sugar lev...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus for at least 12 months
- HbA1c: 7.5-10.0%
- An antidiabetic regimen that has been stable for at least 3 months
- Able and willing to perform SMBG testing as per protocol
Exclusion
- Use of any insulin preparations other than NPH or glargine within the past 6 months
- Pregnancy, breastfeeding, intention to become pregnant within the next 12 months, or judged to be using inadequate contraceptive measures (adequate contraceptive measures includes: sterilization, intrauterine devices, oral contraceptives, or consistent use of barrier methods)
- Known or suspected allergy to trial product or agents related to trial product
Key Trial Info
Start Date :
June 26 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 29 2004
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00791895
Start Date
June 26 2003
End Date
November 29 2004
Last Update
February 24 2017
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Phoenix, Arizona, United States, 85006
2
Novo Nordisk Investigational Site
La Jolla, California, United States, 92093-0694
3
Novo Nordisk Investigational Site
La Jolla, California, United States, 92093-0831
4
Novo Nordisk Investigational Site
DeLand, Florida, United States, 32720